By Nigam Arora & Dr. Natasha Arora
For the first time in two decades, the FDA has approved a new Alzheimer’s drug. The drug is from Biogen (BIIB). There is a great unmet need for Alzheimer’s treatment. Can you imagine investors getting richer by correctly buying the stocks of companies that produce effective Alzheimer’s drugs? Fortunately, The Arora Report subscribers owned the stock of Biogen before the FDA drug approval and are now sitting on nice gains.
Should investors who do not own Biogen stock rush out now to buy the stock of Biogen on the Alzheimer’s drug news? The newly approved Alzheimer’s drug from BIIB is not a slam dunk.
Key Positive Points
- Demand from patients will be high. Existing treatment options only attempt to treat the symptoms, not the underlying disease like Aduhelm, the Alzheimer’s drug from Biogen.
- Doctors are going to feel ethically compelled to prescribe Aduhelm.
- Insurance companies and Medicare are going to be under tremendous pressure to cover the drug.
Key Negative Points
- Aduhelm is priced at $56,000 per year. This does not include costs associated with the monthly infusions or the routine follow-ups and testing for serious side effects.
- A majority of patients are unlikely to benefit. Only one of the studies showed slowed cognitive decline. In that study, only 22% of participants benefited, all of whom received the high dose.
- The side effects are serious. Forty percent of study participants who received the high dose had subsequent brain swelling.
Zones
For those following the Good Way, the Buy Now rating is 🔒 (To see the locked content, please take a 30 day free trial) .’
For those following the Best Way, the buy zone is 🔒. BIIB is trading at $407.14 as of this writing.
New subscribers, please read your Getting A Running Start Guide to learn about the Good Way and the Best Way.
The maximum recommended quantity is 50% of full core position size for aggressive investors.
Those who are not aggressive may want to consider a smaller position size.
Please read Trade Management Guidelines to learn about position sizing.
The first target zone is 🔒. The prior first target zone has already been met where many subscribers took partial profits. The second target zone is 🔒. If the stock catches the attention of the momo crowd or the meme crowd, this stock being pushed up to 🔒 is not out of the question.
What To Do Now
Those in the stock may consider continuing to hold.
Those not in the stock may consider following the parameters given above.
Alzheimer’s Portfolio
FDA approval of Biogen drug for Alzheimer’s will increase investment in Alzheimer’s drug discovery. There will be significant opportunities for prudent investors. The Arora Report is in the process of putting together an Alzheimer’s portfolio that will be available only to paying subscribers.
Alzheimer’s is a terrible disease. A new patient is diagnosed with Alzheimer’s in the United States every 65 seconds. More than 5.8 million Americans are living with Alzheimer’s. For those who are over 65, one in 10 has Alzheimer’s dementia.
Trades posted on The Arora Report Market Blog have produced unrivalled performance since 2007. These trades have been scrutinized in real-time by thousands of investors across the globe. This provides easy verification of performance for newcomers to this site. Only those trades are included in the performance where the entry post was made available to subscribers to The Arora Report Market Blog. When the entry post is made available only to the paying subscribers and not posted in real-time on The Arora Report Market Blog, the resulting performance of the trade is not credited in the performance table. There are very nice gains on this trade but since the entry trade was not posted here for the free subscribers in real-time but only made available to the paying subscribers, handsome profits on this trade will not be added to the performance of The Arora Report Market Blog shown on the table.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
